Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 74.30

+0.2%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	6/20/2011 12:40:39 PM
	of 4676

Piper Jaffray Updates On ISIS Following Shareholders Meeting By BenzingaStaffT Benzinga Staff Writer June 17, 2011 8:11 AM Symbols: ISIS Tags: Piper Jaffray, Isis Pharmaceuticals Inc. Posted in: Analyst Color, Analyst Ratings Share Email Article Print Article Piper Jaffray is maintaining its Neutral rating and its $10 price target on Isis Pharmaceuticals (NASDAQ: ISIS) following the company's annual meeting with shareholders. In the report, Piper Jaffray states, “ISIS hosted a webcast presentation of its annual Shareholders Meeting highlighting the commercial opportunity for mipomersen, its advancing pipeline, and progress with new generation 2.5 antisense chemistry. We look for partner Genzyme/Sanofi-Aventis to file an MAA with the European Medicines Agency (EMEA) in both Homozygous Familial Hypercholesterolemia (HoFH) and the most severe high cholesterol patients in July. ISIS expects to file a BLA in HoFH in the U.S. in 2H:11. Beyond Mipo ISIS has a deep pipeline of 24 partnered or wholly owned antisense drugs in clinical development for a variety of disease areas. We see unrecognized value in this pipeline and believe mipomersen is approvable despite liver safety concerns.” ISIS closed yesterday at $8.86. Read more: benzinga.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next